Spinraza remains a big product for Biogen, but has seen its sales go into reverse as competition in SMA treatment has emerged ...

Biogen is planning to trial its Spinraza spinal muscular atrophy (SMA) drug in patients who have not responded properly to Novartis' gene therapy Zolgensma, combining the two ultra-expensive ...

Zolgensma as an intravenous infusion has been approved in the U.S. for children under 2 years with SMA since 2019. The intrathecal version injects the gene therapy directly into the spinal cord ...

The Swiss drugmaker's one-time therapy, branded as Zolgensma, is already approved ... Other approved treatments include Biogen's spinal injection Spinraza, and Roche-PTC Therapeutics' oral drug ...

Patients can receive a single infusion of Zolgensma. The price of the drug was determined based on that for Spinraza, an existing drug. While Spinraza costs about 9.5 million yen per dosage and ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

Spinraza – approved in the US in 2016 and ... By contrast, Evrysdi and Zolgensma are expected to generate $2.78bn and $2.13bn in 2030, respectively.